OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum
May. 17, 2018
Forum to be held in Chicago, IL, on June 1, 2018
NANTES, France, May 17, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE) today announces that Alexis Peyroles, chief executive officer, will provide a Company update, including recent accomplishments and future plans, at the upcoming 4th Annual Immuno-Oncology: BD&L and Investment Forum. The Forum is being held on June 1, 2018 in Chicago, in parallel to the international annual American Society of Clinical Oncology (ASCO) meeting.
Details of the presentation:
-- Date and Time:June 1, 2018,2:40 PM Central Time -- Session: Track D -- Location: Waldorf Astoria Chicago Hotel, Sinclair Ballroom -- Webcast:https://www.youtube.com/watch?v=fp2UK5znKtk
About the Annual Immuno-Oncology: BD&L and Investment Forum
Sachs Associates, building upon its many years of expertise in organizing premier partnering and investor meetings in Europe and the United States, organizes the Annual Immuno-Oncology: BD&L and Investment Forum. This forum, which annually takes place on the first day of ASCO, is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. The conference includes more than 250 delegates and dozens of presentations by listed and private biotechnology companies seeking licensing & investment opportunities and working to strengthen industry ties.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Neoepitopes innovation (Tedopi®) is today in Phase 3 in advanced lung cancers (NSCLC) after checkpoint inhibitors failure (anti PD-1 and anti PD-L1). A global license and collaboration agreement was signed in April 2018 with Boehringer Ingelheim to develop checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody), for the treatment of advanced solid tumors. An option to license was exercised in July 2016 by Janssen Biotech to continue clinical development of FR104 (an anti CD28 mAb) in auto-immune diseases after positive phase 1 results. A 2-step license option was signed in 2016 with Servier Laboratories to develop OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) to develop the product up to the completion of a phase 2 clinical trial planned in autoimmune bowel disease and Sjogren disease. The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical portfolio offers a diversified risk profile.
Click and follow us on Twitter and Linkedln
OSE Immunotherapeutics U.S. Media: LifeSci Public Relations Sylvie Détry Matt Middleman, M.D. Sylvie.firstname.lastname@example.org email@example.com +33 143 297 857 +1 646 627 8384 French Media: FP2COM U.S. and European Investors Florence Portejoie Chris Maggos firstname.lastname@example.org email@example.com +33 607 768 283 +41 79 367 6254
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.
This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website.
Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.